Allium leafminer ( Loew) is an emerging invasive pest of crops and has been threatening crop production in the eastern United States since its introduction in 2015. can cause substantial economic loss in leek crops when late instars tunnel into the lower portion of the plant, which often renders the crop unmarketable. With limited management tools that are cost-effective and practical, especially for leeks produced in organic systems, we examined the attractiveness of other crop species that might be considered in a trap cropping strategy. In 2021 and 2022, controlled environment choice tests and field trials were conducted to evaluate host preference of among crop species including chives, scallion, an onion and scallion hybrid, and leek. We also assessed preference of P. gymnostoma for scallions that varied in size/age. Results from field trials indicated that only chives had more oviposition marks, cumulative numbers of eggs, and a higher density of larvae and pupae than leeks. Larger/older scallions had more oviposition marks and higher densities than smaller ones in controlled environment choice tests, but this size/age preference was not evident in field trials. Based on our findings, chives could be considered as a potential trap crop for minimizing damage in leek crops.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926477 | PMC |
http://dx.doi.org/10.3389/finsc.2023.1233130 | DOI Listing |
Vaccines (Basel)
December 2024
Center for Drug Evaluation, National Medical Products Administration, Zone 2, No. 22 Guangde Street, Beijing Economic and Technological Development Zone, Beijing 100076, China.
The concept of "platform technology" gained prominence after the Ebola outbreak and since then has become essential to international vaccine (prophylactic vaccines against infectious disease) regulatory frameworks. Its significance was further amplified during the COVID-19 pandemic, where platform technology enabled the rapid development and approval of vaccines, optimizing regulatory processes, and enhancing global public health responses. As a transformative tool, platform technology streamlines product development, allowing for the reduction in the number of clinical trials or exemption from certain clinical trials and facilitating cross-referencing in regulatory submissions.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Avian Diseases, College of Veterinary Medicine and Center for Avian Disease, Jeonbuk National University, Iksan 54596, Republic of Korea.
Duck virus hepatitis (DVH), caused by duck hepatitis A virus (DHAV), poses significant challenges to duck farming due to high mortality rates in young ducklings. Despite the widespread use of live attenuated vaccines, the genetic diversity within DHAV strains has diminished their cross-protection efficacy. This study aimed to evaluate the cross-protective efficacy of current DHAV-1 and DHAV-3 vaccines against genetically divergent wild strains.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Osivax, 70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France.
In a Phase 2a, double-blind, placebo-controlled study including healthy participants aged 18-55 years, OVX836, a nucleoprotein (NP)-based candidate vaccine, previously showed a good safety profile, a robust immune response (both humoral and cellular) and a preliminary signal of protection (VE = 84%) against PCR-confirmed symptomatic influenza after a single intramuscular dose of 180 µg, 300 µg or 480 µg. : Using the same methodology, we confirmed the good safety and strong immunogenicity of OVX836 at the same doses in older adults (≥65 years), a key target population for influenza vaccination. : Significant humoral (anti-NP IgG) and cellular (interferon gamma (IFNγ) spot-forming cells per million peripheral blood mononuclear cells and specific CD4 IFNγ T-cells) immune responses were observed at the three dose levels, without clear dose-response relationship.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA.
Background/objectives: Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants worldwide. Maternal immunization to protect younger infants is supported by evidence that virus-neutralizing antibodies, which are efficiently transferred across the placenta from mother to fetus, are a primary immune mediator of protection. In maternal RSV vaccine studies, estimates of correlates of protection are elusive because many factors of maternal-fetal immunobiology and disease characteristics must be considered for the estimates.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Núcleo de Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas 96010-610, Rio Grande do Sul, Brazil.
Vaccination is essential for maintaining animal health, with priority placed on safety and cost effectiveness in veterinary use. The development of recombinant live-attenuated vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!